Skip to main content

Table 1 Changes of ER-β scores between treatment groups

From: Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

  A P T Total
Pre-treatment    
Mean ± SD 3.21 ± 2.81 3.21 ± 2.63 4.17 ± 2.57 3.51 ± 2.67
Median (minimum–maximum) 3 (0–8) 4 (0–7) 5 (0–8) 4 (0–8)
Total (n) 24 28 23 75
Post-treatment    
Mean ± SD 4 ± 2.31 2.93 ± 2.45 5 ± 2.04 3.91 ± 2.41
Median (minimum–maximum) 4 (0–7) 4 (0–7) 6 (0–8) 4 (0–8)
Total (n) 25 28 23 76
  1. A: anastrozole group; P: placebo group; T: tamoxifen group; SD: standard deviation.
  2. ANOVA with repeated measures using rank transformation: treatment (p = 0.3312) and group × treatment (p = 0.3052).